• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Healthcare·HLA.AX
Share

Healthia Limited Stocks

A$ 0Last Updated 23.03.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

A$ 122.11M

A$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Healthia Limited provides health services in Australia. It operates through three segments: Feet & Ankles; Bodies & Minds; and Eyes & Ears. The company operates podiatry and retail footwear; physiotherapy, hand therapy, occupational therapy, exercise physiology, and speech pathology clinics; and optometry and audiology stores, as well as manufactures and sells orthotic devices. It also offers foot care services, hand and upper limb therapies, orthopaedic, optometry, audiology, pilates, custom orthotic manufacturing services, and medical products to podiatrists, hospitals, medical centres, nursing homes, and allied health professionals. The company was incorporated in 2018 and is based in Bowen Hills, Australia.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is overpriced on P/E, 'cheap' on EV/EBITDA, undervalued o

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

05.08.2026 08:30

Weak sales of Wegovy overshadowed Novo's "clearly less-than-impressive" forecast revision

05.08.2026 07:30

Shein is aiming for a valuation of up to $40 billion in its Hong Kong IPO — Reuters

05.08.2026 01:35

SpaceX Exceeded Revenue Expectations: Revenue Nearly Doubled Thanks to Starlink

05.08.2026 01:18

The S&P 500 hit a new record high for the first time since June, driven by earnings reports and hopes that the Strait of Hormuz would reopen

05.08.2026 00:27

SpaceX Shares Fell 8% After First-Quarter Earnings Report: Online

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026